AR024334A1 - Vacunas adn para animales de compania y de deporte - Google Patents

Vacunas adn para animales de compania y de deporte

Info

Publication number
AR024334A1
AR024334A1 ARP000102879A ARP000102879A AR024334A1 AR 024334 A1 AR024334 A1 AR 024334A1 AR P000102879 A ARP000102879 A AR P000102879A AR P000102879 A ARP000102879 A AR P000102879A AR 024334 A1 AR024334 A1 AR 024334A1
Authority
AR
Argentina
Prior art keywords
company
improvement
dna vaccines
dna vaccination
sports animals
Prior art date
Application number
ARP000102879A
Other languages
English (en)
Inventor
Jean-Charles Fischer Laurent
Barzu-Le Roux Simona
Jean-Christophe
Adonnet Francis
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9907604A external-priority patent/FR2794648B1/fr
Application filed by Merial Sas filed Critical Merial Sas
Publication of AR024334A1 publication Critical patent/AR024334A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Mejora de la eficacia y de la proteccion inducida por la vacunacion ADN contra los virus de la familia de los Paramyxoviridae y contra los virus herpes, enlos animales de companía y de deporte. La mejora de la vacunacion ADN se lleva a cabo o bienpo r la formulacion de la vacuna con un lípido cationico quecontiene una sal de amonio cuaternario, DMRIE, o bien por modificaciones en la secuencia nucleotídica que codifica al antígeno de interés, y/o por insercionesde intrones y/o inserciones desecu encias nucleotídicas que codifican para péptidos senal, o bien por la adicion de GM-CSF, o bien por sus combinaciones.Vacunas así obtenidas.
ARP000102879A 1999-06-10 2000-06-12 Vacunas adn para animales de compania y de deporte AR024334A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907604A FR2794648B1 (fr) 1999-06-10 1999-06-10 Vaccins adn pour animaux de compagnie et de sport
US14449099P 1999-07-19 1999-07-19

Publications (1)

Publication Number Publication Date
AR024334A1 true AR024334A1 (es) 2002-10-02

Family

ID=26234993

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102879A AR024334A1 (es) 1999-06-10 2000-06-12 Vacunas adn para animales de compania y de deporte

Country Status (11)

Country Link
EP (1) EP1185662B1 (es)
JP (1) JP2003502345A (es)
KR (1) KR100768114B1 (es)
AR (1) AR024334A1 (es)
AU (1) AU782154C (es)
BR (1) BR0011732B1 (es)
CA (1) CA2375320C (es)
CZ (1) CZ20014392A3 (es)
NZ (1) NZ515993A (es)
PL (1) PL210451B1 (es)
WO (1) WO2000077043A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
FR2825280B1 (fr) * 2001-06-01 2005-04-15 Merial Sas Vaccination contre le virus de l'immunodeficience feline
EP1689858B1 (en) 2003-11-13 2013-05-15 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
CN101208104B (zh) 2005-04-25 2012-10-31 梅瑞尔有限公司 Nipah病毒疫苗
RS51996B (en) * 2005-09-16 2012-04-30 Merial Ltd. Freeze dried vaccine stabilizers
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
RU2530555C2 (ru) 2008-04-17 2014-10-10 ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН Стимуляция иммунного ответа энантиомерами катионных липидов
WO2010135747A1 (en) 2009-05-22 2010-11-25 Genocea Biosciences Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
EP2861245B1 (en) 2012-06-15 2019-10-16 PDS Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
CN104164409A (zh) * 2014-07-18 2014-11-26 中国人民解放军军事医学科学院军事兽医研究所 含有犬gmcsf基因的重组犬瘟热病毒及其制备方法
CN104958283A (zh) * 2015-06-02 2015-10-07 北京盛大康成医疗技术有限公司 弱碱性皮肤粘膜清洗消毒组合物及其制造方法和用途
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
KR101694676B1 (ko) 2015-12-10 2017-01-10 우진 비앤지 주식회사 말 선역 질병원인 국내 분리 스트렙토코커스 이콰이 균주 및 이를 포함하는 백신
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
CN113924111A (zh) 2019-01-04 2022-01-11 勃林格殷格翰动物保健美国公司 减毒的支气管败血性博德特菌菌株、包含该减毒的菌株的口服疫苗及其制备和使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
WO1994027435A1 (en) * 1993-06-01 1994-12-08 Life Technologies, Inc. Genetic immunization with cationic lipids
JP3745370B2 (ja) * 1994-03-30 2006-02-15 ヴァイロジェネティクス コーポレイション イヌヘルペスウイルスｇＢ、ｇＣおよびｇＤの、核酸およびアミノ酸配列とその利用
CA2214029A1 (en) * 1995-04-25 1996-10-31 Magda Marquet Single-vial formulations of dna/lipid complexes
ES2109189B1 (es) * 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
CA2253229A1 (en) * 1996-04-29 1997-11-06 Riccardo Wittek Polynucleotide vaccine against canine distemper
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
AU1987197A (en) * 1997-03-10 1998-09-29 Heather Lynn Davis Gene delivery to mucosal epithelium for immunization or therapeutic purpose
WO2000024428A2 (en) * 1998-10-23 2000-05-04 Heska Corporation Cationic lipid-mediated enhancement of nucleic acid immunization of cats

Also Published As

Publication number Publication date
NZ515993A (en) 2004-04-30
EP1185662B1 (fr) 2011-03-02
AU5540500A (en) 2001-01-02
WO2000077043A2 (fr) 2000-12-21
BR0011732B1 (pt) 2014-02-04
PL352212A1 (en) 2003-08-11
CZ20014392A3 (cs) 2002-06-12
KR20020012271A (ko) 2002-02-15
AU782154B2 (en) 2005-07-07
BR0011732A (pt) 2002-03-05
CA2375320A1 (en) 2000-12-21
PL210451B1 (pl) 2012-01-31
KR100768114B1 (ko) 2007-10-17
AU782154C (en) 2006-02-09
EP1185662A2 (fr) 2002-03-13
CA2375320C (en) 2013-02-19
WO2000077043A3 (fr) 2001-07-19
JP2003502345A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
AR024334A1 (es) Vacunas adn para animales de compania y de deporte
ES2254833T3 (es) Formula de vacuna polinucleotida, preferentemente para el tratamiento de enfermedades respiratoiras en bovinos.
Romero et al. Single capripoxvirus recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease
ES2629860T3 (es) Vectores virales recombinantes
Kuate et al. Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies
Edbauer et al. Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin-neuraminidase gene
EP0954332B2 (fr) Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
Nusbaum et al. Protective immunity induced by DNA vaccination of channel catfish with early and late transcripts of the channel catfish herpesvirus (IHV-1)
ES2070866T3 (es) Vacunas recombinantes contra la coccidiosis.
FR2751225A1 (fr) Formule de vaccin polynucleotidique aviaire
PL191551B1 (pl) Kompozycje immunogenne, plazmidy, zastosowania plazmidów, zestawy oraz szczepionki
WO1997048370A3 (en) Vaccines comprising synthetic genes
Fischer et al. Rabies DNA vaccine in the horse: strategies to improve serological responses
NO944245L (no) Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner
MXPA01013302A (es) Vacunas para el virus de la parainfluenza (piv) quimerico para humanos-bovinos atenuadas.
Fooks et al. Immunization of mice with plasmid DNA expressing the measles virus nucleoprotein gene
HUP0203974A2 (hu) Javított DNS-oltóanyagok háziállatokhoz
EP1439856A4 (en) RECOMBINANT TOLLWOOD VACCINES AND METHOD FOR THEIR PREPARATION AND USE
ES2283150T3 (es) Mutantes del virus de la rabia atenuados estables y vacunas vivas de los mismos.
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
Boyle et al. Influence of dose and route of inoculation on responses of chickens to recombinant fowlpox virus vaccines
WO1998052603A3 (en) An influenza enveloped dna vaccine
DK177298B1 (en) Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines
CY1105176T1 (el) Χιμαιρικα νουκλεϊνικα οξεα και πολυπεπτιδια του ιου της λυσσας
TW200801034A (en) Novel sea lice vaccine

Legal Events

Date Code Title Description
FC Refusal